3647 results for «686»
3647 results
Inflammation and cardiovascular risk
21 May 2026 – From EuroPCR 2026
Exploring the interplay between inflammation and cardiovascular risk, this session reviews contemporary research on residual risk post-PCI, inflammatory markers in coronary artery disease especially in type 2 diabetes and ACS, and prognostic tools including lipoprotein(a) and systemic inflammation indices.
Modern risk prediction in TAVI
21 May 2026 – From EuroPCR 2026
This session examines modern risk prediction models in transcatheter aortic valve implantation (TAVI). It presents novel scoring systems, the prognostic significance of cardiac damage extent and progression, and the impact of multivalvular disease, enhancing patient stratification and outcome prediction.
Overcoming complications with intracoronary imaging
21 May 2026 – From EuroPCR 2026
Explore challenging cases of intracoronary imaging complications, highlighting recognition, management, and resolution of complex vascular and mechanical issues encountered during coronary interventions.
Refining management of NSTEMI
21 May 2026 – From EuroPCR 2026
This session refines NSTEMI management by exploring advanced diagnostic tools, risk stratification, and tailored revascularization strategies, including bleeding risk assessment and dual antiplatelet therapy considerations.
A randomised trial comparing imaging-guided PCI with Orsiro vs Xience
18 May 2021
Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...
Authors :
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation
05 Sep 2023
Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.
Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...
Author
BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial
26 Aug 2023
Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.
BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...
Author
